|

Orelabrutinib Clinical Trials

22 actively recruiting trials across 2 locations

No change since May 2026

Also known as: ICP-022, Induction phase, Obinutuzumab, Rituximab, Yinuokai

Pipeline

Phase 2: 11Phase 3: 7Phase 4: 1Phase 2/3: 1

Top Sponsors

  • Ruijin Hospital5
  • Zenas BioPharma (USA), LLC2
  • The First Affiliated Hospital with Nanjing Medical University2
  • The First Affiliated Hospital of Soochow University2
  • Beijing InnoCare Pharma Tech Co., Ltd.2

Indications

Other20 trials

A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
Phase 3
A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Phase 3
Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma
Phase 4
Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment
Phase 3
Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
Phase 3
Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL
Phase 2
Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation
Phase 2
Genotype-guided Treatment in DLBCL
Phase 3
ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
Phase 2/3
MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL
Phase 2
Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial
Phase 2
Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL
Phase 2
Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL
Phase 2
Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease
Phase 2
Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)
Phase 2
Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment
Phase 2
Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL
Phase 2
Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma
N/A
Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients
N/A
Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage Ⅰ-Ⅱ MALT Lymphoma
Phase 2

Pheonix, Arizona1 trial

A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

Arizona Neuroscience Research, LLC

Phase 3

Scottsdale, Arizona1 trial

A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

Perseverance Research Center, LLC (PRC)

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.